OPV plus BCG

PreclinicalBiologic

BBandim Health Project

OPV plus BCG is one of 5 biologic programs targeting Infants. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfantsCompleted

InfantsPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Infants

#DrugCompanyPhaseTrials

Aranesp

Amgen

Phase 2

2 2

Dopram

HHikma Pharmaceuticals LLC

Phase 3

1 3

Cysteine Hydrochloride

Novartis

Phase 1

1 4

Ivig

Argenx

Preclinical

1 5

OPV plus BCG

BBandim Health Project

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infants1 trial

Sex-Differential Health Interventions In Low-Birth-Weight Infants

Completed·BBandim Health Project·N/A·NCT00625482

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OPV plus BCG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OPV plus BCG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OPV plus BCG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bandim Health Project company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: BBandim Health Project

OPV plus BCG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Infants1 trial

References

Drug Info

Quick Facts

Related News